Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
NBRV was delisted on the 31st of July, 2023.
39 hedge funds and large institutions have $71.1M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 13 closing their positions.
4,933% more call options, than puts
Call options by funds: $453K | Put options by funds: $9K
51% more capital invested
Capital invested by funds: $47M → $71.1M (+$24.1M)
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
17% less funds holding
Funds holding: 47 → 39 (-8)
62% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.1M |
| 2 |
FI
Fosun International
Hong Kong,
China
|
+$1.45M |
| 3 |
Renaissance Technologies
New York
|
+$710K |
| 4 |
FM
Frazier Management
Seattle,
Washington
|
+$533K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$350K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.25M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$4.83M |
| 3 |
USAA
United Services Automobile Association
San Antonio,
Texas
|
-$469K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$170K |
| 5 |
LCM
Laurion Capital Management
New York
|
-$152K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| – | -$7K | -19 | Closed |
|
|
TRCT
52
Tower Research Capital (TRC)
New York
| – | -$6K | -16 | Closed |
|
53
Barclays
London,
United Kingdom
| – | -$545 | -1 | Closed |
|
NBRV Hedge Fund Activity: Q1 2019 in Review
39 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q1 2019, worth a combined $71.1M — up 51% from $47M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of NBRV and 5 opened new positions — a net loss of 8 holders — while 9 trimmed existing stakes and 13 added.
The largest buyer was Fidelity Investments, adding an estimated $3.1M. The largest seller was Wellington Management Group, exiting entirely with an estimated $5.25M sold.
- 39 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q1 2019, down from 47 in Q4 2018.
- Funds reported $71.1M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q1 2019, up 51% quarter-over-quarter.
- 5 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q1 2019 and 13 closed out, a net change of -8 holders.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q1 2019 was Fidelity Investments, an estimated $3.1M added.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q1 2019 was Wellington Management Group, an estimated $5.25M sold.
Based on aggregated 13F filings for Q1 2019.